JUBBONTI (denosumab-bbdz)


Drug overview for JUBBONTI (denosumab-bbdz):

Generic name: DENOSUMAB-BBDZ (den-OH-sue-mab)
Drug class: Hypercalcemia Agents
Therapeutic class: Endocrine

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.
DRUG IMAGES
  • No Image Available
    No Image Available
The following indications for JUBBONTI (denosumab-bbdz) have been approved by the FDA:

Indications:
Glucocorticoid-induced osteoporosis
Loss of bone mineral density (BMD) due to androgen deprivation therapy
Loss of bone mineral density (BMD) due to aromatase inhibitor therapy
Osteoporosis in male patient
Osteoporosis in postmenopausal woman at high risk for fracture


Professional Synonyms:
Androgen ablation induced osteoporosis or osteopenia
Androgen deprivation induced osteoporosis or osteopenia
Androgen suppression induced osteoporosis or osteopenia
Bone loss from androgen ablation
Bone loss from aromatase inhibitor
Glucocorticoid hormone-induced osteoporosis
Glucocorticoid induced osteoporosis
Glycocorticoid-induced osteoporosis
Loss of BMD due to aromatase inhibitor therapy
Osteoporosis in men
Osteoporosis or osteopenia due to ADT
Osteoporosis or osteopenia due to androgen ablation therapy
Osteoporosis or osteopenia due to aromatase inhibitor therapy
Postmenopausal osteoporosis in woman with high fracture risk
Postmenopausal osteoporosis with high fracture risk